1 Though the last decade has seen accelerated advances in techniques and technologies 2 to perturb neuronal circuitry in the brain, we are still poorly equipped to adequately dissect 3 endogenous peptide release in vivo. To this end we developed a system that combines in 4 vivo optogenetics with microdialysis and a highly sensitive mass spectrometry-based 5 assay to measure opioid peptide release in freely moving rodents. 6 7 18 specificity for full length vs. truncated peptides that contain identical binding epitopes.
Introduction 8
Neuropeptides are the largest class of signaling molecules in the central nervous 9 system where they act as neurotransmitters, neuromodulators, and hormones 1 . In vivo 10 neuropeptide detection is technically challenging as neuropeptides can be rapidly 11 cleaved by peptidases and undergo posttranslational modifications. To further 12 complicate detection, neuropeptides are found at orders of magnitude lower 13 concentrations compared to classical neurotransmitters (i.e. glutamate, GABA, and 14 the biogenic amines) and adsorb to a variety of surfaces during sample handling 2,3 . 15 16 For decades, neuropeptides have been assayed with immunoaffinity-based techniques 17 due to their high sensitivity 4,5 . However, selectivity remains a concern due to poor antibody the nucleus accumbens (NAc) can modulate both rewarding and aversive behaviors 13, 14 .
48
We showed that photostimulation of dynorphin (dyn) cells in the ventral nucleus 49 accumbens shell (vNAcSh) elicited robust aversive behavior, while photostimulation of 50 6 dorsal NAcSh dyn (dNAcSh) cells induced a place preference that was positively 51 reinforcing, however, no successful measurements of optogenetically-evoked 52 neuropeptide release in vivo have been reported to date. Furthermore, few reports have 53 extensively investigated regional distinctions within the NAc shell and no reports to our 54 knowledge have successfully measured optogenetically-evoked neuropeptide release in 55 vivo.
57
To quantify evoked-neuropeptide release in anatomically and behaviorally distinct regions, 58 we pursued a method to reliably detect neuropeptides in the nucleus accumbens during 59 photostimulation of opioid-containing neurons. We developed a custom optogenetic-60 microdialysis (opto-dialysis) probe that simultaneously provides photostimulation with the 61 ability to sample local neurochemical release in awake, freely moving mice. We 62 established a targeted nLC-MS method to analyze the opioid peptides dyn (fragment 63 dynorphin A1-8) and enkephalins (leu-and met-), as well as dopamine, GABA and 64 glutamate. We applied these techniques to precisely investigate regional differences 65 between the vNAcSh and dNAcSh neuropeptide release dynamics. This system allows 66 quantification of neuropeptide release while directly controlling cell-type selective neuronal 67 firing in the NAcSh.
69

Results
70
To establish a quantitative assay, we used a custom synthesized isotopically labeled dyn 71 (DYN*, YGGFLRRI with isotope 13 C6 15 N1-leucine) with a mass shift of +7 and a +3.5 m/z 72 shift (+2 charge state) as an internal standard (IS) to account for variability during the LC 73 injection, surface adsorption, and ionization efficiency. High concentration injections of 74 DYN* were fully resolved by the mass spectrometer and did not result in cross talk with 75 endogenous dyn ( Fig. 1a & b) , demonstrating that the addition of labeled DYN* does not 7 contribute to or interfere with the endogenous dyn signal, while maintaining a similar 77 retention time. To further validate the use of DYN* as an internal standard when detecting 78 opioid peptides we prepared a linear calibration curve with a mixture of dyn, Leu-79 Enkephalin (LE) and Met-Enkephalin (ME) standards spiked with DYN* and detected all 80 four compounds within 5 min following loading and desalting the sample on the column.
81
Four distinct peaks are shown in the reconstructed ion chromatographic trace, confirming 82 the separation and reliable detection of all three opioid peptides with isotopically labeled 83 DYN* in one sample (Fig. 1c ). The addition of the DYN* isotope to our assay further 84 improves quantification by improving relative standard deviation for repeated injections of 85 standards ( Fig.1d-f 
90
For in vivo detection in freely moving mice, we developed a customizable microdialysis 91 probe (i.e. customizable length, depth and sampling area) with an integrated fiber optic to 92 locally sample proximal to the site of photostimulation in the brain (Fig. 2a , 93 Supplementary Fig. 1a-e ). Traditional dialysis probes incorporate inlet and outlet tubing 94 encased in a semi-permeable membrane enclosed with epoxy, and further encased in a 95 stiff cannula for rigidity and robustness. To minimize the size of the opto-dialysis probe we 96 did not include the final external casing and instead took advantage of the natural rigidity 97 of the fiber optic to support the dialysis inlet-outlet assembly ( Fig. 2a , Supplementary 98 Fig. 1a-e ). This resulted in a maximal probe diameter of 480 μm. To maximize 99 concentrations of peptides entering the probe, we used a 60 kDa molecular weight cutoff, 100 polyacrylonitrile membrane with a slight negative charge for optimal peptide recovery 101 8 (AN69, Hospal, Bologna Italy) 2,4 and showed we can measure changes in peptide stock 102 concentration within the 15 min fraction collection time (Fig. 2b ).
104
To evoke and measure in vivo peptide release we injected AAV5-EF1a-DIO-ChR2-eYFP 105 in to either the vNAcSh or the dNAcSh of preprodynorphin-IRES-cre (dyn-cre) mice and 106 implanted the custom opto-dialysis probes 3 weeks later (Fig. 3a) . Following recovery (Supplementary Fig. 2a -c) and if correct anatomical 118 probe placement and viral expression were confirmed ( Supplementary Fig. 3a and b) .
119
In the current study 81.1% (15/18) of the mice were included in the analysis.
121
A significant increase in dyn was detected in dyn-cre positive mice during photostimulation 122 in both the vNAcSh (interaction effect; t=3.941, p<0.001) and dNAcSh (interaction effect; 123 t=3.012, p=0.003), compared to control mice (Fig. 3b) . Interestingly, in the vNAcSh there 124 was also a sustained increase in dyn after photostimulation (interaction effect; t = 2.499, 125 p = 0.014) (Fig. 3b) . Dyn release during photostimulation was also significantly higher in 126 the vNAcSh compared to the dNAcSh (interaction effect; t=2.749, p=0.007) and post 127 9 stimulation (interaction effect; t=2.806, p=0.006) (Fig. 3b ). Photostimulation of vNAcSh 128 dyn neurons was previously shown to cause aversive behavior, consistent with early 129 pharmacological studies which linked dyn with negative emotional states 13, 15 . Here we 130 demonstrate sufficiently discrete dynorphin detection to measure different levels of peptide 131 in two regions of the NAc shell separated by 1mm.
133
We simultaneously detected robust release of LE and ME in both the vNAcSh and Fig. 3c ). Converse to this, we observed a significant increase in ME 138 during photostimulation of dyn-containing cells in the vNAcSh (comparing cre+ and cre-, 139 interaction effect; t=2.824, p=0.006). However, the same effect was not significant in the 140 dNAcSh (comparing cre+ and cre-, t=1.78, p=0.053) ( Fig. 3d) . Importantly, we observed 141 a significant change in ME in the dNAcSh when compared to its baseline (t=1.94, p=0.033) 142 and there was no significant difference between the effect of photostimulation in ventral 143 and dorsal (i.e. both are increased). However, the lack of a significance between Cre+ and 144 Cre-in dNAcSh is likely due, at least in part, to the fact the baseline levels of opioid 145 peptides in dNAcSh are higher than the vNAcSh (7.114 pM versus 2.71 pM, respectively).
146
Though data is represented as % of baseline the range of absolute dialysate concentration 147 detected for dyn was 0.28-0.44 pM in dNAcSh and 0.13-0.28 pM in vNAcSh; 148 pM in dNAcSh and 1.30-2.24 pM in vNAcSh; ME 6.19-8.69 pM in dNAcSh and 2.57-4.11 149 pM.
151
To determine if peptide release corresponded with small molecule neurotransmitter 152 release, we applied a benzoyl chloride (BzCl) derivatization LC-MS method to monitor 3 10 small molecules, dopamine, GABA and glutamate in dialysis samples 16, 17 . Interestingly, 154 dopamine increased in the dNAcSh during photostimulation (interaction effect; t=5.007, 155 p<0.0001), which persisted following stimulation (interaction effect; t=2.081, p=0.039) 156 ( Fig. 3e) . Levels of GABA also increased in the vNAcSh following photostimulation 157 (t=2.363, p=0.020) and had a prolonged response (t=4.744, p<0.0001) (Supplementary 158 Fig. 4a ). There were no significant changes in glutamate levels during photostimulation in 159 either vNAcSh or dNAcSh ( Supplementary Fig. 4b ).
161
Discussion
162
The data show that photostimulation of dyn-containing cells in the vNAcSh and dNAcSh 163 results in a detectable increase in dyn release, which is greater in the vNAcSh. This result 164 correlates with previous behavioral data demonstrating that dyn release likely drives a 165 region dependent preference and aversion behavior 13 . We observed a significant increase 166 in LE and dopamine during photostimulation in the dNAcSh. Importantly, we previously 167 observed a preference behavior when photostimulating dyn cells in the dNAcSh and these 168 data suggest that the preference may be related, at least in part, to the detected increases 169 in dopamine and LE. Furthermore, many studies have shown that levels of both dopamine 170 and LE increase during preference or reward [18] [19] [20] . Importantly, using this method it is not 171 possible to know whether LE is derived from pDyn or pENK but in future experiments we 172 can combine this with conditional knockout approaches to selectively delete the peptides 173 in specific cell types, so that we can later determine what happens to these signals in the 174 absence of expression of particular peptides in D1 vs D2 cells and subregions. In addition, 
181
Furthermore, an alternative, presynaptic regulation of DA release from VTA to NAc 182 projections is also plausible, and recently been investigated by multiple groups 22,23 .
184
The observed changes in GABA in both vNAcSh and dNAcSh are as predicted due to the 185 fact that dyn-containing medium spiny neurons are GABAergic. The observed increase in 186 ME is intriguing, as ME is not released from the same cells as dynorphin. There has been 187 some evidence to suggest that enkephalins play a role in regulating disruptions in 188 homeostasis following chronic exposure to drugs of abuse 24, 25 . Specifically, increases in 189 enkephalin release during drug withdrawal has been shown through peptide tissue 190 content, mRNA levels and microdialysis of extracellular enkephalins in a number of brain 191 regions including the nucleus accumbens 26 . Concurrently, studies have measured 192 increases in dynorphin expression during withdrawal [27] [28] [29] [30] [31] . It seems possible therefore that 193 when we are stimulating the release of dynorphin (perhaps mimicking some aspects of 194 withdrawal), levels of met-enkephalin increase in response to this, as a homeostatic 195 mechanism to relieve this withdrawal-like state. This release profile is unique to the 196 vNAcSh suggesting that this region is critical in the regulation of hedonic homeostasis.
197
Though we have previously shown that dyn mRNA expression is similar in the vNAcSh 198 and dNAcSh 13 , it would be ideal to also verify the expression pattern and distribution of 199 the enkephalins in the vNAcSh and dNAcSh. Finally, it should be noted that this detection 200 technique maintains the poor temporal resolution of peptide and other microdialysis 201 approaches. Therefore, conclusions regarding the differential transmitter and peptide 202 release profiles should be tempered by the long time course of collection.
204
The ability to detect multiple peptides and small molecules in vivo with high sensitivity, as 205 shown here demonstrates the potential of this method. It is, however, important to 206 acknowledge limitations and future considerations with this methodology. Due to the 207 structural similarity between ME/LE and dyn, we included DYN* as our only internal 208 standard. An ideal assay would include isotopically labeled internal standards for each 209 analyte of interest, however, the addition of analytes to detect in the ion trap reduces 210 points per peak and complicates the chromatogram.
212
In this current method the 3 peaks of interest, LE/ME/dyn, all appear in the chromatogram 213 in close proximity between 4-5.5 minutes, which may not seem ideal. A way to resolve this 214 would be to flatten out the solvent gradient to better resolve the peaks 215 chromatographically, however the length of the run would be longer, therefore reducing 216 overall throughput. Here it takes 18 minutes from injection-to-injection and it is important 217 to note that the peaks, while not fully resolved in time, were fully resolved by mass-to-218 charge ratio, so the separation was sufficient in this case. It is important to consider this 219 delicate balance going forward to detect more peptides in an extended experimental 220 paradigm and for concurrent detection of other peptides within individual samples.
222
Here we only detected dyn1-8, LE and ME, but as mentioned in the introduction there are 223 many more fragments that could be involved or altered that we have not measured. We 224 primarily focused on dyn1-8 as this was the fragment that was the most reliable to detect 225 in developing this methodology. Since we were at the early stages of method development 226 it was crucial to limit variability where possible. The limitations to in vivo detection of 227 neuropetides by microdialysis with LC-MS has been thoroughly explored and are largely 228 due to absorption and lack of adequate recovery 2 . In this current method organic modifiers 229 13 are not added to the perfusate for dialysis or to the sample in the vial, as we validated that 230 there was no peptide carryover/stickiness in the LC-MS lines without such agents.
231
However, it has been shown that the addition of an organic modifier, like acetonitrile, to a 232 sample could be optimized for each peptide fragment and improve quantitation by 233 reducing stickiness to the vial and LC-MS fluidic pathway 2 . This approach, however, 234 appears to be dependent on each individual peptide.
236
This new approach, we describe here allows for detection of cell-type specific evoked in 237 vivo neuropeptide release within neural circuits to be observed during freely moving Fabrication of the optogenetic fiber optic probe was made as previously described 13, 32, 33 .
272
Fabrication of the microdialysis probe and opto-dialysis probe are described in the 273 supplemental information. inserting probes were similar to those previously described 8, 13, 32, 34 optic (opto-dialysis probe). Implanted probes were secured using two bone screws and 294 dental cement. Mice were allowed to recover 24 h with free access to food and water prior 295 to baseline collection for microdialysis studies.
297
For microdialysis studies, the fiber optic was connected to the laser via a tether running 298 through a Ratturn (Bioanalytical Systems, Inc.) along with microdialysis perfusion lines. 
335
Isotopically labeled DYN* (+7 mass shift, isotopically labeled 13 C6 15 N1-leucine) internal 336 standard was detected using m/z values of 495 à 438. In vitro recovery of a 1 mm probe 337 for dyn, LE, and ME were 12 ± 2%, 13 ± 3%, and 13 ± 2%.
339
Fresh dyn, LE, and ME standards, spiked with DYN* for the opioid assay were prepared 340 daily. Standards were analyzed with nLC-MS at 0.01, 0.05, 0. 1, 1, 10, 20, 50 , and 100 pM 341 concentrations in triplicate to determine linearity, reproducibility, and limits of detection.
342
Opioid analytes were normalized to DYN*. Limits of detection for dyn, LE, and ME were 343 0.2 ± 0.04, 0.5 ± 0.3, and 0.6 ± 0.4 pM, respectively, in 5 μL and were determined each 344 day of experimentation. Average carry over across all experiments for dyn, LE, and ME 345 were 0.8 ± 0.03%, 0.3 ± 0.3%, and 0.3 ± 0.2% determined by running the 346 highest calibration point immediately followed by a blank and integrating the peak area 347 across the same time. Mice that had average basal levels above the limits of detection 348 and had appropriate probe placement and virus expression were used for the study. 
